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Recent studies have demonstrated that covalent grafting of a sin-
gle histidine residue into a twin-chain aliphatic hydrocarbon com-
pound enhances its endosome-disrupting properties and thereby
generates an excellent DNA transfection system. Significant
increase in gene delivery efficiencies has thus been obtained by
using endosome-disruptingmultiple histidine functionalities in the
molecular architecture of various cationic polymers. To take advan-
tage of this unique feature, we have incorporated L-histidine (N,N-
di-n-hexadecylamine) ethylamide (LH) in the membrane of hepato-
cyte-specific Sendai virosomes containing only the fusion protein
(F-virosomes (Process for Producing aTargetedGene (Sarkar,D. P.,
Ramani, K., Bora, R. S., Kumar, M., and Tyagi, S. K. (November 4,
1997) U. S. Patent 5,683,866))). Such LH-modified virosomal enve-
lopeswere four timesmore (p< 0.001) active in terms of fusionwith
its target cell membrane. On the other hand, the presence of LH in
reconstituted influenza and vesicular stomatitis virus envelopes
failed to enhance spike glycoprotein-induced membrane fusion
with host cell membrane. Circular dichroism and limited proteoly-
sis experiments with F-virosomes indicated that the presence of LH
leads to conformational changes in the F protein. The molecular
mechanism associated with the increased membrane fusion
induced by LH has been addressed in the light of fusion-competent
conformational change in F protein. Such enhancement of fusion
resulted in a highly efficient gene delivery system specific for liver
cells in culture and in whole animals.
Completion and annotation of the human genome sequence has sig-
nificantly enhanced the possibility of using designer DNA for gene ther-
apy. Nonetheless, in spite of the first gene therapy trial 14 years ago, and
numerous clinical trials thereafter, successful gene therapy remains elu-
sive. The threemain hurdles of widespread belief have been bolstered as
(i) delivery, (ii) delivery, and (iii) delivery (1). It turns out that the most
up-hill task toward ensuring clinical success of gene therapy is to design
safe, efficacious and target-specific transfection vectors. Toward
designing such gene carriers, significant progress has been made on
gene transfection by novel non-glycerol-based histidylated cationic
amphiphiles, presumably via the endosome-disrupting properties of the
histidine functionalities (2). Histidine residues in amphipathic peptide
antibiotics are also known to promote efficientDNAdelivery intomam-
malian cells in vitro by favoring endosomal escape of the DNA mole-
cules at low pH (3). Complexes of recombinant adenoviruses and cati-
onic lipids/polymers have been tested for the enhancement of
therapeutic index for the treatment of cystic fibrosis (4). The beneficial
role of such complexes was clearly envisaged by the amplification of
binding and entry of adenovirus particles into host cells. However,
despite all these encouraging results, its failure in targeted gene transfer
in whole animal and inherent cytopathic/cytotoxic side effects limit its
applications in liver gene therapy (5). Because liver is an ideal organ for
somatic gene delivery as well as the therapeutic target for hepatic dis-
eases (6), we had developed a virus-based liver-specific delivery system
(F-virosomes (FV))4 (34) efficient in transferring foreign genes into
human hepatoblastoma cells (HepG2) in culture and mouse/rat hepa-
tocytes in vivo. F-virosomes exploit the membrane fusogenic property
of Sendai virus F glycoprotein and the high affinity terminal -galac-
tose-containing ligands (present on F glycoproteins) for the asialogly-
coprotein receptors on the hepatocyte surface (7). Upon tight binding to
the asialoglycoprotein receptors, F-virosomes undergo fusion both at
the level of plasma membrane and endosomal membrane followed by
receptor-mediated endocytosis and deliver the entrapped molecules
into the cytosol (8–10). We also observed that fusion efficiency of Sen-
dai virus F protein is much reduced in the absence of its native attach-
ment glycoprotein, hemagglutinin neuraminidase (HN) (7). To over-
come such impediments, we tested the efficacy of histidine functionality
in disrupting endosomes. Thus, we have incorporated LH molecules in
the F-virosomal membrane and systematically assessed its ability to
enhance the binding and fusion with the target cells (cultured hepato-
cytes andmouse liver) asmonitored by transgene expression.We report
for the first time that histidine functionality of a cationic amphiphile
specifically enhances F glycoprotein-induced membrane fusion and
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results in efficient gene delivery.5 The possible mechanisms of LH-in-
duced activation of F-virosome-target membrane fusion have also been
investigated.
MATERIALS ANDMETHODS
Reagents
N-4-Nitrobenzo-2-oxa-1,3-diazole phosphatidylethanolamine (NBD-PE)
was purchased fromAvanti Polar Lipids. SM2 Bio-Beads were obtained from
Bio-Rad. Triton X-100 was obtained from Aldrich. Lysozyme (chicken egg
white, IUB 3.2.1.17), trypsin (type III), dithiothreitol, wheat germ agglutinin
(WGA), sodium azide, EDTA (disodium salt), rhodamine isothiocyanate
(RITC), bafilomycin A1 were purchased from Sigma. L-Histidine (N,N-di-n-
hexadecylamine) ethylamide (LH) (molecular formula,C40H81N5Cl2O,molec-
ular weight, 752.5) and N,N-di-n-hexadecyl-N-2-aminoethylamine (LC)
(molecular formula, C34H74N2Cl2, molecular weight, 581) were synthesized
(Fig.1)andstoredasdescribedearlier (2).Dulbecco’smodifiedEagle’smedium,
DPBS, fetal bovine serum, and antibiotics were obtained from Invitrogen.
Monoclonal antibody against GFP was procured from BD Bioscience Clon-
tech.VITROGENwaspurchased fromCOHESIONTechnologies Inc. (Palo
Alto, CA). Other reagents used were also of the highest grade commercially
available.
Virus
Sendai virus (Z strain) and influenza virus X:31 (A/Aichi/68;H3N2)
were grown in the allantoic sac of 10–11-day-old embryonated chicken
eggs. The virus was harvested and purified following standard proce-
dures (7). Vesicular stomatitis virus (Indiana) was grown on monolayer
cultures of baby hamster kidney (BHK-21) cells and purified as
described elsewhere (11).
Cells
HepG2 cells (human hepatoblastoma cell line) and HeLa cells were
obtained from American Type Culture Collection and were grown as
described earlier (7). Fresh red blood cells were prepared from healthy
Swiss albino mice in accordance with the norms of the Animal Ethics
Committee, University of Delhi South Campus laws and regulations.
Preparation of Loaded F-virosomes
F-virosomes were prepared following published/patented proce-
dures. Cationic amphiphiles (LH and LC) were incorporated in reconsti-
tuted viral membrane as described earlier for making NBD-PE-labeled
virosomes (7). Briefly, the LH and LC compounds dissolved in solvents
(chloroform:methanol, 2:1, v/v) were dried in a glass vial separately
under nitrogen to form a thin film. The supernatant from the detergent
extract of pure Sendai virus (50mg of protein), containing only the viral
F protein and the lipids, was added to the respective LH and LC films and
incubated at 20 °C for 30 min with gentle shaking. The detergent was
removed by SM2 Bio-Beads to form the virosomes. The amount of
amphiphiles incorporated into the virosomal membranes (LHFV and
LCFV) was analyzed by high performance liquid chromatography after
purifying the virosomal preparations through a continuous sucrose gra-
dient as described elsewhere (12). NBD-PE-labeled influenza virosomes
(HA containing virosomes) with LH and LC were made according to
earlier protocols with modifications as above (13). Similarly, labeled
vesicular stomatitis virus virosomes (GV)with LH and LCwere prepared
following a published procedure (11). The plasmid pEGFP-N1 (Clon-
tech, isolated using aQiagenMegaprep unit) coding for enhanced green
fluorescent protein (EGFP) under the control of cytomegalovirus pro-
moter and RITC-lysozyme were entrapped in various virosomal prepa-
rations following our patented protocol (8, 10). Liposomes containing
LH/cholesterol and LC/cholesterol were prepared as reported earlier (2).
The virosome preparations were passed through 26-gauge needle 20
times and their particle size analyzed by a Photon Correlation Spec-
trometer (photon correlation spectrometry model: Photocor FC) using
the software Flexcor/DynaLS provided by the Photocor company. The
system was calibrated using 200-nm silica/latex particles (supplied by
Photocor FC). Trypsinization, limited proteolysis by proteinase K, heat
treatment (56 °C for 30 min), and DNase I digestion of virosome sam-
ples were carried as described elsewhere (8, 9, 14).
Membrane Fusion-mediated Targeted DNA/Protein Delivery to
Cells in Culture
Hemolysis and lipid mixing (fluorescence dequenching of NBD-PE)
assay for virosome-cell fusion were carried out as described earlier (7).
Binding of NBD-PE-labeled virosomes and fusion-mediated delivery of
RITC-lysozyme to the target cells were performed following our pub-
lished protocol (7, 8). Targeted cytosolic delivery of pEGFP-N1 DNA to
HepG2 cells in culturewas essentially carried out as described elsewhere
(9). For fusion-mediated delivery (of entrapped RITC-lysozyme and
DNA) experiments to target cells in culture with bafilomycin A1 (175
nM, a potent inhibitor of endosome acidification), the drug was mixed
with loaded virosomes after dilutionwith themedium.The gene expres-
sionwas assessed by recording EGFP fluorescence in aNikon Eclipse TE
300 epifluorescent microscope attached to a digital camera (Digital
sight DS-5M). For immunofluorescence studies, cells were washed with
PBS twice and fixed in 2% paraformaldehyde in PBS at room tempera-
ture, followed by permeabilization with 0.1% Triton X-100 containing
0.5 MNH4Cl in PBS for 10min. The cells were blocked in 5% fetal bovine
serum containing PBS at room temperature for 30 min and incubated
with anti-GFP A.v. monoclonal antibody (JL-8) overnight at 4 °C fol-
lowed by washing with PBS and incubation with fluorescein isothiocya-
nate-labeled goat anti-mouse IgG (Sigma). The cells were then visual-
ized in a Nikon microscope for fluorescein isothiocyanate fluorescence
as above. In a parallel assay, cell extracts were processed for evaluation
of EGFP expression byWestern analysis using the ECLdetection system
(Santa Cruz Biotechnology) and also by fluorometric quantitation (15).
Total DNA/RNA isolation and PCR/RT-PCR amplification from the5 Patent applied.
FIGURE 1. Structure of lipids.
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cells in culture were performed as described below for in vivo studies
with mice. All experiments were independently repeated at least three
times.
Administration of Loaded Virosomes to Balb/cMice and
Gene Expression in Isolated Hepatocytes
Twelve-week-old female Balb/c mice (18 g) were injected intrave-
nously into the tail vein (in accordancewith the guidelines of theAnimal
Ethics Committee, University of Delhi South Campus), with DNA-
loaded virosomes (0.8 mg F protein containing 4 g of pEGFP-N1) in a
final volume of 0.2 ml of DPBS containing 2 mM Ca2. Injection of the
equivalent amount of free DNA and heat-treated loaded virosomes in
DPBS served as appropriate controls. After 2 days post-injection, paren-
chymal cell types (hepatocytes) were isolated as described in an earlier
report by a member of our group (10) and plated on 12-well plastic
plates (Falcon, BD Biosciences) coated with VITROGEN as per their
protocol in Dulbecco’s modified Eagle’s medium with 10% fetal bovine
serum. Following incubation in CO2 for 24 h, plates were examined for
EGFP expression as described above. The genomic DNA and total RNA
were extracted by standard procedures (16) and subjected to PCR
amplification/RT-PCR of the EGFP gene (transcripts).
(i) PCR Amplification of EGFP Gene—Total genomic DNA isolation
from hepatocytes was done using TRIzol. The primer set designed for
EGFP amplification included the following: sense, 5-TGACCCT-
GAAGTTCATCTGCACCA-3; antisense, 5-TTGATGCCGTTCT-
TCTGCTTGTCG-3. PCR amplification was performed using Taq
DNA polymerase (Invitrogen) with a cycling profile of 94 °C for 45 s,
55 °C for 45 s, 72 °C for 45 s, for 30 cycles, and a final extension of 72 °C
for 10 min (same in the case of -actin primers, Stratagene). A specific
amplified product of 361 bp of the EGFP gene was visualized by
ethidium bromide staining on a 1.2% agarose gel and transferred to
nylon membrane. As a control, the -actin gene was also amplified and
a product of 650 bp was obtained. Southern hybridization was per-
formed to further confirm the specificity of the PCR products using a
720-bp NotI/HindIII EGFP gene fragment derived from the plasmid
pEGFP-N1, labeled with [-32P]dCTP (by the random primer-labeling
technique).
(ii) RT-PCR Amplification of EGFP Gene-specific Transcript—Total
hepatic RNA from various mice or fromHepG2 cells was isolated using
TRIzol reagent (Invitrogen). DNase I (Invitrogen)-treated RNA was
reverse transcribed using Superscript RNase H RT (Invitrogen) and
gene-specific antisense primer as per the manufacturer’s protocol. PCR
amplification (30 cycles) of the RT product was performed using high-
fidelity Platinum TaqDNA polymerase (Invitrogen) with a cycling pro-
file as mentioned before. The amplified product of 361 bp of the EGFP
gene was visualized by ethidium bromide staining on a 1.2% agarose gel
and transferred to nylonmembrane and subsequently Southern hybrid-
ized. As a control, -actin mRNA was also amplified by RT-PCR for
each sample and a product of 650 bp was obtained.
Luciferase Gene Expression in Parenchymal Liver Cells 48 h after
Injection of pBVluc-loaded Virosomes to Balb/cMice
Following intravenous (tail vein) injection (0.8 mg of F protein con-
taining 4 g of plasmid DNA) of various pBVluc (containing the firefly
luciferase gene under control of the cytomegalovirus promoter as
described earlier by Ramani et al. (10))-loaded virosomes (FV, LCFV,
LHFV, and LHFV(H)), parenchymal cells were isolated as above. The
cells were washed twice with Tricine-buffered saline and suspended in
the same. For luciferase assay, the Triton X-100-solubilized cell lysate
(from 1 107 cells) was mixed with luciferase assay buffer containing 1
mM luciferin (Roche Molecular Biochemicals). Luciferase activity (in
mV) was measured in a 1250 Luminometer (BIO-Orbit, Finland) as
described earlier (10).
Histological and Immunohistochemical Methods
Four groups ofmice (threemouse per group) were injected (0.8mg of
F protein containing 4 g of plasmid DNA) with various pEGFP-N1-
loaded virosomes (FV, LCFV, LHFV, and LHFV(H)). After 6 months a
portion of each liver from the injected mice was immediately fixed in
Bouins fixative and dehydrated through graded alcohol and xylene fol-
lowed by embedding in paraffin wax. Such embedded tissues were cut
into 5-m sections, deparaffinized, and rehydrated. For immuno-
staining, sections were washed in PBS for 10 min and blocked with 3%
bovine serum albumin in PBS for 1 h at 37 °C. Subsequently, sections
were incubated with EGFP-specific monoclonal antibody (JL-8) for 1 h
at 37 °C. After three washes with PBS, sections were incubated with
fluorescein isothiocyanate-labeled goat anti-mouse IgG at 37 °C for 1 h.
All antibody dilutions weremade in 1.5% bovine serum albumin in PBS.
Following extensive washes with PBS, the slides were counterstained
with Mayer hematoxylin, washed in distilled water, and mounted in
glycerol. The specificity of immunostaining was verified by the use of
PBS in place of primary antibody (data not shown). The sections were
examined using fluorescence microscopy (Nikon fluorescein isothio-
cyanate filter set) and photographed (magnification,20).
Circular Dichroism
The CD spectra were recorded on a Jasco (J-715) spectropolarimeter
fittedwith a Peltier-based temperature controller (PTC-43). The instru-
ment was calibrated with ()-10-camphorsulfonic acid. Subsequently,
the spectral measurements of the virosome samples (0.04 mg/ml F pro-
tein in LHFV and LCFV samples) were made using a 0.2-cm path-length
cell at room temperature with constant purging of nitrogen. Each pro-
tein sample was subjected to 30 scans to obtain the final spectrum. The
respective buffer baselinewas subtracted from the spectra of the protein
samples and data were presented as ellipticity expressed in millidegree.
RESULTS
Fusion of F-virosomes with Target Cell Membrane Is Enhanced by
Histidylated Cationic Lipid—To evaluate the particle size, virosomal
preparations were subjected to photon correlation spectrometry meas-
urements. It revealed the mean diameter of FVs to be 181 nm, which
conforms well to the average size reported earlier by transmission elec-
tron microscopy (17), on the other hand, LHFV and LCFV preparations
were found to be 298 and 232 nm, respectively (data not shown). 
potential measurements of these virosomes reflected net negative
charge for FV and net positive charge for both LHFV and LCFV. The
membrane fusion activity of F protein in FV is well correlated with its
ability to hemolyse various RBCs upon WGA-mediated binding of F
protein to cell surface sugar molecules (7). Therefore, to begin with
mouse, RBC was chosen as appropriate target cells with a view to check
and compare the efficiency of membrane fusion by various virosomal
preparations in the presence ofWGA.As shown in Fig. 2a, various doses
of LHmolecules significantly enhanced the hemolytic activity of LHFVs.
With 2 mg, LH incorporated into 50 mg of total Sendai virus protein
resulted in a 4-fold increase in hemolytic activity. The specificity of the
effect of LH was established by parallel control with LC (having the same
amount of positively charged head group but lacks histidinemoiety, Fig.
1), which did not affect hemolysis over FVs alone. Strikingly, same
amount of LH in LH/CHOL liposomes mixed with FVs did not affect
hemolysis over FVs alone. HNFVs, containing HN that markedly
Modified Sendai Viral Envelopes for Targeted Gene Delivery
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enhances its lytic activity (7), served as a positive control, and incorpo-
ration of LH and LCmolecules in HNFVs did not enhance the hemolytic
activity any further. Similar results were also obtained with RBCs from
human and rabbit (data not shown). The high performance liquid chro-
matography analysis of the sucrose density gradient-purified virosomes
showed 85% efficiency of incorporation using 2 mg of LH against 50 mg
of Sendai virus (Fig. 2a, inset). The gradient purification of virosomes
(12) ensured the co-grafting of LH and LC molecules with F protein in
FIGURE 2. a, effect of LH dose (and various treatments) on hemolysis ofmouse RBCs induced by virosomes. Various virosomal preparations (20g of F protein) were added tomouse
RBCs (0.5% v/v) in a total volume of 1 ml in PBS (pH 7.4), in the presence of 6 g of WGA. The mixture was incubated on ice for 40 min with occasional shaking and then at 37 °C for
30 min. The reaction was terminated by chilling the mixture on ice and spun at 1,000 g for 10 min. The amount of hemoglobin released in the presence of 0.3% Triton X-100 was
taken as 100% lysis. The points are average of three independent experiments. Inset shows the dose-dependent incorporation of LH in virosomal membrane. A, FV(H), heat-treated
F containing virosomes; B, LHFV(H), heat-treated LHFV; C, LCFV(H), heat-treated LCFV; D, T.LHFV, trypsin-treated LHFV containing 2.0 mg of LH; E, LH/CHOLFV, liposomes of LH and
cholesterol with amolar ratio 1:2mixedwith FV; F, LCFV, LC containing FV;G, FV, F containing virosomes;H–L, LHFV containing 0.5, 1.0, 2.0, 4.0, and 8.0mgof LH, respectively;M, HNFV,
HN, and F containing virosomes. b, electrophoretic mobility of various virosomes (20 g of protein) resolved by SDS-10% PAGE and stained with Coomassie Blue. c, effect of LH and
LC in binding of virosomes at 4 °Cwithmouse RBCs in the presence of 6gofWGA.NBD-PE-labeled virosomeswere used tomonitor binding in terms of fluorescence unit. The points
are average of three independent experiments. d, effect of LH and LC in binding (in terms of NBD fluorescencemeasurement) of NBD-PE-labeled virosomes at 4 °C with HepG2/HeLa
cells (in thepresenceof 10mMsodiumazide). As azide is known to completely inhibit endocytosis (8), the values reflect only the amount of virosomesbound to the surfaceof the cells.
The points are average of three independent experiments. e, kinetics of hemolysis inducedby virosomes. Virosomes (20gof protein)were added tomouse RBCs (0.5%v/v) in a total
volumeof 1ml in PBS (pH 7.4), with 6g ofWGA. Themixturewas incubated at 4 °C for 60min and then at 37 °C for different times. Hemolysis wasmeasured (calculated as described
in a) as a function of time. Each data point represents an average of three independent experiments.
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the viral membrane. Similar profile of incorporation (and size) was also
obtained with HA containing virosomes and GV (data not shown). The
incorporation profile of LC in FVs followed the same trend (data not
shown). Calculations based on the protein/lipid composition of viro-
somes, molecular weights of F (HA and G) and cationic lipids, about 60
molecules LH (and LC), were estimated to be associated with one mole-
cule of F (HA and G) protein in the respective virosomal membranes
(having 2 mg of LH with 50 mg of Sendai, influenza, and vesicular sto-
matitis virus). All further experiments were performed at this
stoichiometry.
NBD-PE-labeled FVs, LHFVs, and LCFVs, containing equivalent
amounts of F protein of identical electrophoretic mobility (Fig. 2b), had
equal affinity for mouse RBCs and HepG2 cells but showed negligible
attachments toHeLa cells at 4 °C (Fig. 2, c and d). Because ourmain goal
is to demonstrate targeted gene delivery in liver cells using LH-modified
FVs, HepG2 cells are included at this point as the only target cells of
choice (7) to establish the role of LHmolecules in enhancing membrane
fusion induced by F protein in culture conditions.HeLa cells are taken as
negative controls to reveal the binding specificity of the terminal -ga-
lactose moieties of F protein to the asialoglycoprotein receptors on the
hepatocyte cell surface. As shown in Fig. 2e, the presence of LH in the
viral membrane markedly enhanced the kinetics (8-fold increase) as
well as the extent of hemolysis. LH/cholesterol liposomes mixed with
FVs failed to exert such an effect. Fluorescent micrographs showing
escalated movement of NBD-PE (dequenching of fluorescence) from
LHFVs to mouse RBCs indicated membrane fusion (compare panels A
and B with C in Fig. 3) and the transfer of RITC-lysozyme from loaded
virosomes to an increased number (about 2-fold) of HepG2 cells (com-
pare panel 1 and 2 with 3 in Fig. 4a) indicated core mixing. This is also
in agreement with higher (3-fold) RITC fluorescence in HepG2 cells
as in the case of LHFV (Fig. 4b). It corroborated the fast kinetics (almost
FIGURE 3. Fusion of NBD-PE virosomes with mouse RBCs. NBD-PE-labeled virosomes
(10g of protein) were incubated at 4 °C for 60minwith 0.5%mouse RBCs in 1ml of PBS
(pH 7.4) containing 6 g of WGA. The virosome-cell complexes were washed once at
300 g (4 °C/2 min) in PBS, and cells were suspended in 1 ml of cold PBS. After 30 min
incubation at 37 °C, cells were photographed with Nikon GFP filter set (magnification,
10). A, FV; B, LC FV; C, LH FV; D, LH FV(H). H, stands for heat-treated loaded virosomes.
FIGURE 4. a, internalization of RITC-lysozyme into
HepG2 cells delivered through virosomes. Loaded
virosomes (40 g of F protein, containing 4 g of
RITC-lysozyme) were incubated with HepG2 cells
in 12-well culture plates. After incubation at 37 °C
for 1 h, cells were washed with DPBS (pH 7.4) con-
taining 5 mM EDTA (EDTA stripping to remove the
bound but not fused virosomes with HepG2 cells
as described by Bagai and Sarkar (8)) and sub-
jected to fluorescence microscopy with a barrier
filter of 590 nm (magnification,10). 1, FV; 2, LCFV;
3, LHFV; 4, LHFV in presence of bafilomycin A1; 5,
LHFV(H); 6, LHFV incubated with HeLa cells. (H)
stands for heat-treated loaded virosomes. b, -fold
increase of RITC fluorescence (arbitrary units) in
HepG2 cells. Upon fluorescence microscopy as in
a, cell lysates were made following the procedure
of Dandekar et al. (15) and fluorescencewasmeas-
ured in a spectrofluorometer taking an equal
amount of proteins (100 g). The values are aver-
age of three independent experiments.
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4-fold) and higher extents of fluorescence dequenching ofNBD-PE (Fig.
5) with target cells at neutral pH. Such accelerated movement of
NBD-PE was not observed with FVs mixed with LH/cholesterol lipo-
somes (data not shown). It was also confirmed that at low temperature
(4 °C), LH in the virosomal membrane did not have any influence on
binding to RBCs (Fig. 3, panels A–C) andHeLa cells (Fig. 2d). Hemolysis
experiments carried out with DNA-loaded virosomes at pH 5.0 showed
similar results (data not shown). Bafilomycin A1, which inhibits endo-
some acidification by blocking the action of H-ATPase, could not
diminish the fusion-mediated RITC-lysozyme transfer from LHFVs
(Fig. 4a, panel 4, during co-incubation, and also the 15 min pre- and
postincubation condition results were the same as that of co-incuba-
tion, data not shown). LH/cholesterol liposomes, when co-incubated
with all types of loaded virosomes, did not affect at all the F protein-
mediatedmembrane fusion (membrane and coremixing events) at both
pH 7.4 and 5.0 (data not shown). Notably, LH could not influence the
activation of HA and G protein-induced fusion of viral envelopes with
HepG2 cells (Fig. 6).
LH Containing F-virosomes Augment TargetedGene Transfer in Vitro—To
assess the effect ofDNA loading on the size of various virosomes, the prepara-
tionswerecheckedbyphotoncorrelationspectrometryanalysis.Uponentrap-
ment of pEGFP-N1DNA in FVs (50g of DNA/mg of F protein), the size of
the loaded virosomes showed a slight increase to 232 nm, whereas, the same
amountofDNA loaded inLCFVs andLHFVs (80gofDNA/mgof Fprotein)
exhibited an almost 2-fold increase (data not shown). However, as observed
with FVs earlier (9), all three types of FV-associated DNA was found to be
DNase I resistant, indicating that itwas entrapped rather thanadsorbedon the
virosomalmembrane.Nodetectable leakage ofDNAwas observed fromsuch
loaded vesicles incubated with PBS or mouse plasma/fetal bovine serum at
37 °C for about 6 h and heat-treated virosomes (56 °C for 30min).Membrane
fusion activity of these loaded preparationswas assessed by their ability to lyse
mouseRBCsand fusewithHepG2cells in culture and found tobevery similar
to that of their unloaded counterparts (data not shown).
With a view to evaluate the efficiency of gene expressionmediated by
LHFVs, 4g of pEGFP-N1DNA-loaded virosomes were incubated with
HepG2 andHeLa cells for 24 h in the culturemedium.More than 60%of
the HepG2 cells expressed EGFP protein as shown in Fig. 7a, panel 4,
under the influence of LH lipid, whereas FV and LCFVs showed around
20–30%EGFP positive cells (Fig. 7a, panels 2 and 3, respectively). Three
to 4-fold enhancement of gene expression is also corroborated by quan-
titating fluorescence in the cell extracts (Fig. 7b). Heat-treated LHFVs
(Fig. 7a, panel 1) and LHFVs incubated with HeLa cells (Fig. 7a, panel 6)
failed to express EGFP. However, in the presence of bafilomycin A1,
transfection efficiency remained unchanged (Fig. 7a, panel 5) as
observed in the case of lysozyme transfer (Fig. 4a). These results were
further verified with immunofluorescence studies (data not shown)
using specific anti-GFP antibody upon fixing the same cells as in Fig. 7a.
To obtain further support of the expression profile of EGFP expression
in various treatments, cells were processed for Western blot analysis
(Fig. 7c, panel A) and a high level expression (about 3-fold more) was
reconfirmed in the case of loaded LHFVs. To determine whether the
observed differences in gene expression were because of varying effi-
ciencies of DNA delivery and differential transcript synthesis, DNA-
PCR and RT-PCR were performed, followed by Southern analysis from
cells in a parallel experiment (results presented in Fig. 7c, panel B andC,
respectively). A careful comparison of the Southern hybridized specific
band intensities with a standard curve (Fig. 7c, panel D), revealed
2[1,2]-fold more delivery of EGFP DNA under LH influence, keeping
the number of HepG2 cells fixed. Thus, a direct correlation between the
amount of delivered DNA and the level of transgene expression was
observed.
Site-specific Gene Delivery in Whole Animal through LHFV—To
ensure that the transgene expression was exclusive for hepatocytes (in
conformity with the cell-specific nature of the virosomal delivery sys-
tem, in vivo), cells isolated from various organs of mouse, 2 days after
injection of 4 g of DNA-loaded virosomes, were analyzed for EGFP
FIGURE 5. Kinetics of membrane fusion (fluorescence dequenching (FDQ)) of NBD-
PE-labeled various virosomes with HepG2 and HeLa cells. Ten micrograms of NBD-
PE-labeled virosomeswere incubated at 4 °C for 40minwith 1 106HepG2orHeLa cells
in 1ml of DPBS (pH 7.4) containing 1.5mM Ca2. Virosome-cell complexes were washed
three times at 300 g (4 °C/2 min) in cold DPBS buffer to remove unbound virosomes
and cells were suspended in 1ml of prewarmedDPBS and incubated at 37 °C for various
times. Fluorescence was measured at 473/520 nm (excitation/emission) wavelengths
with a spectrofluorometer (model RF-540, Shimadzu Corp, Kyoto, Japan). Percent fluo-
rescence dequenching (%FDQ) was calculated according to the equation: %FDQ 
100 F F0/Ft F0, where F and Ft are fluorescence units at a given time point and in
the presence of 0.3% Triton X-100, respectively, and F0 is fluorescence at time 0. Each
data point represents an average of three independent experiments. Solid lines, HepG2
cells; dotted lines, HeLa cells.
FIGURE 6. Effect of LH on fusion (fluorescence dequenching) of NBD-PE-labeled
influenzaHA (X31)andvesicular stomatitis virusGvirosomeswithHepG2cells.Ten
micrograms of various NBD-PE virosomes were incubated with 1  106 HepG2 cells
separately at 4 °C for 40 min in 1 ml of DPBS containing 1.5 mM Ca2. After removing
unbound virosomes as in Fig. 5, the bound virosome-cell suspension was placed into a
cuvette containing 1 ml of DPBS (pH 5.0), prewarmed to 37 °C, and fluorescence meas-
urements were made after 30 min as described in the legend to Fig. 5. Values indicated
are average of three independent experiments. LCHAV and LHHAV denote influenza HA
(X31) containing virosomeswith LC and LH, respectively. LCGV and LHGVdenote vesicular
stomatitis virus G containing virosomes with LC and LH, respectively. (H) denotes heat-
treated virosomes.
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gene expression. This was critically assessed in intact liver parenchymal
cells at the level of protein (Fig. 8, a and b, and panel A of c), DNA (Fig.
8c, panel B), and mRNA (Fig. 8c, panel C). A remarkable transfection
efficiency (70% of the hepatocytes) was achieved with histidylated
virosomes (Fig. 8a, panel 4) in terms of EGFP-positive liver cells,
whereas greater than 20% of cells exhibited EGFP fluorescence in the
case of FVs (Fig. 8a, panel 2) and LCFVs (Fig. 8a, panel 3). Heat-treated
LHFVs failed to show detectable gene expression as expected (Fig. 8a,
panel 1). Similar -fold increase in EGFP expression (3-fold) was sub-
stantiated from the fluorescence quantitation (Fig. 8b). This superior
nature of histidyl induction of fusion-mediated cytosolic delivery, in
vivo, was further corroborated with immunofluorescence analysis with
the fixed cells (data not shown) and Western analysis (about 2.5-fold
more over controls) in parallel experiments (Fig. 8c, panel A). DNA-
PCR analysis of two mice (Fig. 8c, panel B) (and repeated three times)
reflected almost 2-foldmore delivery of DNAby loaded LHFVs over FVs
and LCFVs to the hepatocytes. RT-PCR analysis of total RNA from
isolated hepatocytes (Fig. 8c, panel C) matched higher DNA delivery.
Failure of the detection of EGFP transcripts in other organs confirmed
the liver-specific delivery of loaded-LHFVs in whole animal (Fig. 8c,
panel D). Moreover, total lymphocytes from blood and cells isolated
from the organs other than liver did not exhibit any EGFP fluorescence
(data not shown). Furthermore, luciferase gene expression profiles in
isolated parenchymal cells (and no significant expression was found in
non-parenchymal cells) from injected mice (Fig. 8d) and immunohisto-
chemical analysis of EGFP expression in liver sections (Fig. 8e) recon-
firmed the supremacy of LHFV-mediated gene delivery and expression
over FV, LCFV, and other appropriate controls. Interestingly, expression
of EGFP in whole liver was sustained until 6 months following a single
injection of loaded virosomes and superior transfection efficiency (in
terms of number of EGFP positive cells) of LHFV over FV and LCFV is
further bolstered. The animals remained healthy and active during the
experiments.
Histidylated Cationic Lipid Induces Conformational Changes in F
Protein—Limited proteolysis experiments have been successfully used
to probe changes in structure, dynamics, and function of proteins (18).
We subjected FV, LHFV, and LCFV to proteinase K digestion to ascer-
tain conformational changes in F protein because of the presence of the
histidylated lipid, which might have enhanced the membrane fusogenic
propensity of F protein. Because it is well known that membrane fusion
induced by Sendai viral F protein with its target cells is pH independent
and fuses both at the cell surface (neutral pH) and acidic endosomal
milieu (12), proteolysis of F protein was carried out at pH 7.4 and 5.0.
The SDS-PAGEanalysis of the proteinaseKdigest shown in Fig. 9 (a and
b) reveals that proteolysis of F protein occurs in much the same way at
both pH values. However, F protein is significantly more susceptible to
proteinase K digestion in the presence of histidylated lipid. Under iden-
tical conditions, about 80% of the protein is digested in LHFV as com-
pared with only 50% in FV and LCFV. These results are indicative of a
FIGURE 7. a, expression of EGFP in HepG2 cells transfected with DNA-loaded virosomes as described under ”Materials and Methods.“ After incubation for 24 h, cells were subjected
to fluorescence microscopy (Nikon eclipse TE 300, Japan) and photographed with a barrier filter of 510 nm (magnification, 10). 1, LHFV(H); 2, FV; 3, LCFV; 4, LHFV; 5, LH FV in the
presence of bafilomycin A1; 6, LHFV incubated with HeLa cells. b, -fold increase of EGFP fluorescence (arbitrary units) in HepG2 cells. This was carried out as described in the legend
to Fig. 4b. The points are average of three independent experiments. c, critical evaluation of EGFP expression.Western blot analysis of EGFP expressed inHepG2 cells in culture, using
anti-GFP antibody. Corresponding Ponceau S-stained proteins on nitrocellulosemembrane reflect loading control (panel A), DNA PCR (panel B), RT-PCR (amplification of EGFPmRNA
using EGFP-specific primers followed by hybridization with EGFP gene probe) (panel C), and Southern hybridization of standard pEGFP-N1 plasmid (panel D). DNA/RNA loading
controls are visualized by -actin expression. G, GFP control; 1, FV; 2, LCFV; 3, LHFV; 4, LHFV(H); H, HeLa.
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conformational change in F protein in the presence of the histidylated
lipid.
Because LHFV was relatively more susceptible to proteinase K diges-
tion as compared with the LCFV and FV, we examined the influence of
histidylated lipid on the conformation of F protein by CD spectroscopy
(Fig. 9c) at both pH 7.4 and 5.0 to mimic the plasma membrane and
endosomal level fusion, respectively. For this, we recorded the far UV
CD spectra of the F protein in the presence and absence of histidylated
lipids. At both pH values (7.4 and 5.0), the spectra of the F protein
exhibited double minima at 222 and 208 nm that are characteristics of
the helical structure. The ellipticity value at 222 nm for F protein in the
presence of LHFV at pH 7.4 was about 15% higher than that of LCFV. At
pH 5.0, this difference was magnified to about 50% relative to LCFV.
Only a slight decrease in negative ellipticity at 222 nmwas noticeable in
LHFV samples at pH 5.0 as compared with pH 7.4. In contrast, the
negative ellipticity at 222 nm was considerably lower at pH 5.0 as com-
pared with pH 7.4 in the case of LCFV samples. LH/cholesterol lipo-
somes when mixed with FVs failed to induce any changes in the CD
spectra. It is interesting to note that LH molecules failed to induce any
such structural alterations of HA and G proteins in their respective
virosomes (data not shown). Taken together, the CD data indicate that
the histidylated lipid exerts specific and significant influence on the
secondary structure of F protein.
DISCUSSION
Sendai, an enveloped animal virus belonging to paramyxovirus fam-
ily, contains two glycoproteins (hemagglutinin neuraminidase (HN)
and fusion factor (F)) in the outer leaflet of its lipid bilayer (19).We have
earlier established that besides conferring attachment function via sialic
acid receptors, HN enhances F protein-mediated membrane fusion of
reconstituted viral envelopes (F- and HN-virosomes) with target cells
(7). Furthermore, loaded HN-depleted virus envelopes (F-virosomes)
are known to selectively fuse with hepatocytes both in culture and in the
whole animal leading to the delivery of proteins, drugs, DNA, and pol-
ymeric nanoparticles (10, 20–22). Considering a distinct role of HN in
viral envelope-cell fusion and its lack of cell type specificity, it is felt that
the F-virosome-mediated gene delivery system needs to be modified
with suitable alternatives. Moreover, the molecular mechanism of HN-
mediated help to F protein in terms of envelope-cell fusion (the fusion
trigger) is yet to be deciphered (23). Working toward these two key
objectives, we have presented evidence for significant enhancement of
membrane fusion-mediated targeted cytosolic delivery of model drug
and genes to liver cells by F-virosomes using a novel histidylated cati-
onic amphiphile.
We first examined the hemolytic activity of the various virosome
preparations (Fig. 2a) as it is closely related to its membrane fusion
activity (7). This was then verified bymore sensitive techniques, such as
lipid and core mixing assays. Although a variation in size of various
virosomes was noticed, the individual preparations were fairly homoge-
neous in size and emphasis was given to the same amount of protein
taken in all cases (Fig. 2b). The reasons for size increase in the case of
lipid-modified FVs are not yet clear. However, it is quite apparent that
the lipids (LH and LC) did not influence the specific binding to mice
RBCs (mediated throughWGA, Fig. 2c and 3) andHepG2 cells (through
F-asialoglycoprotein receptor interaction, Fig. 2d). Therefore, the pos-
sible role of LH in activating the F protein could be ascribed to the
histidyl moiety present in the samemembranousmilieu, at a stoichiom-
etry of 60 molecules of LH to one molecule of F protein. The failure of
such enhancement of hemolysis by co-incubating LH/cholesterol and
FVs with RBCs supports this notion.Moreover, the fact that trypsinized
LHFVs could neither bind to RBCs (data not shown) nor cause any
hemolysis (Fig. 2a) led us to conclude the participation of such LH-
activated F proteins in mediating such enhanced membrane fusion and
that it is not because of any enhanced binding of virosomes to target
cells through histidyl groups. Heat-treated LHFVs (Fig. 2a) failed to
induce hemolysis, thereby supporting the role of active F only in causing
fusion with RBCs. Despite no remarkable reduction of incorporation of
the LH lipid in virosomal membranes (inset of Fig. 2a), the origin of the
striking diminution of hemolysis above 4 mg of LH cannot be explained
presently. The fusion activation of F protein by LH is bolstered by faster
kinetics and a higher extent (about 8-fold) of hemolysis (Fig. 2e) and
measurement of lipid mixing assay with RBCs through NBD-PE
dequenching by fluorescence microscopy (Fig. 3, compare panel Cwith
FIGURE 8. a, in vivo expression of EGFP in mouse hepatocytes. Hepatocytes were isolated from mice, 48 h post-injection as described under ”Materials and Methods.“ After 24 h
incubation at 37 °C in a 5%CO2environment, cellswerephotographed for EGFPexpression asdescribed in the legend to Fig. 7a (magnification,20). 1, LHFV(H); 2, FV; 3, LCFV; 4, LHFV.
(H) stands for heat-treated loaded virosomes. b, -fold increase of GFP fluorescence (arbitrary units) in mouse hepatocytes. This was carried out as described in the legend to Fig. 4b.
The points are average of three independent experiments. c, decisive assessment of EGFP expression. Panel A, Western blot of EGFP expressed inmouse hepatocytes using anti-GFP
antibody andPonceau S-stainedproteins onnitrocellulosemembrane (loading control);G, GFP control; 1, FV; 2, LCFV; 3, LHFV; 4, LHFV(H). Panel B, DNAPCR. Panel C, RT-PCRof the total
RNA isolated from the mouse hepatocytes; G, GFP control; 1, LCFV(H); 2, LHFV(H); 3, FV; 3, FV; 4, LCFV; 4, LCFV; 5, LHFV; 5, LHFV. Panel D, RT-PCR amplification of EGFP mRNA from
various organs of mice injected with DNA-loaded LHFVs, using EGFP-specific primers followed by hybridization with EGFP probes; L, liver; Lu, lung; K, kidney; S, spleen; B, brain; M,
skeletal muscle; G, GFP control. DNA/RNA loading controls are visualized by -actin expression. d, luciferase gene expression in mouse hepatocytes mediated through histidylated
lipid-modified virosomes. Luciferase activity in parenchymal cell typeswas determined as described under ”Materials andMethods.“ Values representmean ( S.D.) from threemice
livers. FD, free DNA. e, efficient and persistent EGFP gene expression inwholemouse liver 6months after injection of DNA-loaded virosomes. Immunohistochemical detection of the
EGFP was carried out as described under ”Materials and Methods“ (magnification,20). 1, LHFV(H); 2, FV; 3, LCFV; 4, LHFV. (H) stands for heat-treated loaded virosomes.
FIGURE 9. a and b, effect of LH incorporation on the susceptibility of F protein (in viro-
somes) to proteolytic digestion by proteinase K. SDS-PAGE stainedwith Coomassie Blue
are visualized following treatment with () and without () proteinase K. a and b indi-
cate digestion at pH 7.4 and 5.0, respectively. The percentage degradation was calcu-
lated by densitometric scanning using ”total lab image software“ (Amersham Bio-
sciences). Duplicate samples are loaded on gels. Bovine serum albumin (BSA) served as
positive control. c, the CD spectra of LHFV and LCFV at pH 7.4 and 5.0 were recorded on a
Jasco (J-715) spectropolarimeter as described under ”Materials and Methods.“
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A and B under “Binding and Fusion”). It is well established that the
fluorescence emission of NBD-PE remains quenched in the virosomal
membrane because of its high-density packing. Upon fusion of the viro-
somal membrane with the target membrane, the phenomenon of “lipid
mixing” ensures the transfer of NBD-PE molecules to the target cell
membranes with concomitant dequenching of its fluorescence (7). The
effect of LH on the coremixing assay by transfer of RITC-lysozyme from
LHFVs to HepG2 cells in culture (Fig. 4, a, compare panel 3 with 1, and
2 and b) further confirms the enhanced and target-specific fusion-me-
diated delivery of virosomal contents at physiological pH. Similar results
were obtained at pH 5.0 (data not shown) conforming the well estab-
lished pH-independent fusion activity of Sendai virus (23). In an attempt
to assess the proposed endosome disrupting nature of LH (2) at pH 5.0
and its role if any, on the observed high efficiency of fusion of LHFVs, a
specific and potent proton pump inhibitor, bafilomycin A1, completely
failed to affect the fusion-mediated delivery of RITC-lysozyme (Fig. 4a,
panel 4). Similarly, histidine-rich amphipathic peptide-mediated pro-
motion of efficient DNA delivery into mammalian cells in culture was
not found to be fully bafilomycin A1-sensitive, indicating that protona-
tion of histidine is not solely responsible for endosome disruption (3).
The more pronounced effect (6-fold) of LH on kinetics of fusion of
NBD-PE-labeled LHFVs with HepG2 cells emphasizes the influence of
the histidyl moiety in enhancing F-induced membrane fusion at both
early and late events (Fig. 5). Furthermore, failure of LH in affecting the
membrane fusion of other analogous envelope spike glycoproteins (HA
and G) indicates the specificity of LH-F interplay (Fig. 6). Taken
together, these results are in support of the belief that histidine head
group-F protein cross-talking, analogous to HN-F interactions, is the
key event in achieving such quantum jump in fusion activity.
About 2-fold increase in the diameter of lipid-modified DNA-loaded
virosomes (LCFVs and LHFVs) is consistent with that of the liposomes
formed with LH andDNA (2). However, themaximum size with amean
diameter 532 nmofDNA-loaded LHFVs did not exhibit any deviation of
fusion function from their unloaded counterparts (data not shown) and
could selectively deliver DNA to the HepG2 cells in culture (Fig. 7) and
hepatocytes in mouse liver (Fig. 8). A remarkable increase in the tar-
geted gene delivery and expression (70%EGFP positive cells), aided by
LH in the case of LHFVs both in vitro and in vivo, represents a significant
development toward the goal of offering an entirely new and promising
class of semiviral delivery vehicles. Furthermore, about 3-fold higher
luciferase gene expressionmediated through LHFV (over FV and LCFV)
in mouse hepatocytes strengthens the role of LH in achieving efficient
gene transfer process (Fig. 8d). Additionally, the real beauty of LHFV-
mediated gene transfer is comprehended from the long lasting (6
months) and efficient EGFP expression in whole liver (Fig. 8e). It is
relevant to state in this context, the safe and non-toxic issues of Sendai
virus components in humans, extrapolating the studies with nonhuman
primates (24). Some recent reviews and research articles on the area of
gene delivery/therapy have underscored the importance of non-viral
and liposomal/virosomal vectors in achieving successful gene therapy in
the near future (25–28). Current clinical trials based on adenoviral vec-
tor-mediated gene transfer for curing inherited metabolic disorders
have suffered serious setbacks following the death of Jesse Gelsinger in
1999 (26), and several other problems including toxic/immunogenic
side effects, failure to integrate into host chromosomes, and low levels of
transgene expression in human hepatocytes (non-replicating cells) (28).
Despite removal of the viral genes in such vectors, potential safety con-
cerns demand efficient non-viral methods for long-term gene transfer
(25). Although several attempts have been made in the recent past, a
high-pressure DNA delivery system (“hydrodynamic” methods)
requires a very large volume of intravenous naked DNA injection into
portal veins without any tissue/cell-specific targeting concerns (28).
Moreover, safety issues are equally important and need to be sorted out.
The present virosomal delivery system being truly at the interface of
viral and non-viral vectors is expected to be adequately safe in compar-
ison to their non-hybrid counterparts. Perhaps, with more similar
manipulations, such modified virosomes will become increasingly diffi-
cult to discriminate from viruses and will suit the “liver gene therapy”
protocol in reality.
Sendai virions exhibiting binding and fusion functionswith host cells,
contain the F protein in the form of a disulfide-linked complex (F1,2),
consisting of two glycopeptides (F1 and F2) that are derived by proteo-
lytic cleavage of an inactive precursor (F0) by a host cell enzyme (29).
The movement of the fusion sequence to the target membrane prior to
the culmination of fusion is believed to be facilitated by the formation of
coiled-coil or helix bundle assembly of the N- and C-terminal heptad
repeat (HR) sequences (30). Therefore, the stability of the secondary
structure of this region is important in determining the rate and extent
of fusion (31). Earlier studies (12) using reconstituted liposomes clearly
indicate a significant increase in -helicity during the cleavage of F0 to
F1,2, reflecting the fusion competent conformation of F protein (F*). In
the present study, CD analyses revealed increases in the helical confor-
mation in F protein (in F-virosomes) in association with LH at both
neutral and acidic pH (Fig. 9c). However, the limited proteolysis exper-
iments suggested that the F protein was more susceptible to proteolysis
in the presence of histidylated lipid (Fig. 9, a and b). These results indi-
cate that histidylated lipid might have stabilized the coiled-coil forma-
tion while partially unfolding the remainder of the molecule that
became more sensitive to proteolysis. Taken together, the proteolysis
and CD results in-frame with the fusion data support the notion of a
gamut of conformational changes of F protein in association with LH
molecules. Induction of conformational changes of F protein by LHmay
thus be presumed as the ”super fusion-competent“ (F**) form of F*. In
this event, LH help to the F*, may be conceptualized as a stabilizer of
helicity of exposed hydrophobic HR sequence. The HR sequences are
highly conserved among all paramyxovirus members and fold into a
6-fold helix bundle during the fusion process (23). The proposition of
the F** state is in agreement with a recent study, where salient three-
dimensional structural features of the fusion-primed Sendai F protein
(F*) have been revealed by electron cryomicroscopy. It has been con-
cluded that to expose the fusion peptide, the fusion-primed ectodomain
of F* has to undergo further conformational changes (32). Additionally,
an indirect support to our hypothesis on F* to F** transition, induced by
LH, may be drawn from a recent observation where a proline replace-
ment of leucine at residue 705 in the heptad repeat region (HR2) of
mitofusin reduces the stability of the HR2 coiled-coil with a concom-
itant reduction of mitochondrial membrane fusion (33). In the light
of the well known HN-F interactions in the intact virions and its
reconstituted envelopes containing both F and HN proteins (7),
work is underway to test the exact contribution(s) of the histidine
moiety to F protein in enhancing the fusion function. Notwithstand-
ing the mechanism, the results presented here highlight the potential
immediate applications of histidylated amphiphile-modified F-viro-
somes in liver “gene therapy.”
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